Gan & Lee Pharmaceuticals vs Imeik Technology Development: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gan & Lee Pharmaceuticals Co Ltd (603087.CG)

Q3 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

September 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Latest27 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Imeik Technology Development Co (300896.CS)

Q3 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

August 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

Latest15 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.